Mesoblast (NASDAQ:MESO) Shares Gap Down to $7.10

Mesoblast Limited (NASDAQ:MESO)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $7.10, but opened at $6.39. Mesoblast shares last traded at $6.53, with a volume of 84,636 shares.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on MESO. Cantor Fitzgerald restated an “overweight” rating on shares of Mesoblast in a research note on Friday, January 12th. StockNews.com lowered shares of Mesoblast from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Mesoblast has a consensus rating of “Hold” and an average target price of $13.67.

Mesoblast Trading Down 7.3 %

The firm has a market cap of $751.30 million, a price-to-earnings ratio of -5.80 and a beta of 3.59. The stock’s 50 day moving average is $3.89 and its 200 day moving average is $2.78.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Mesoblast stock. Lazari Capital Management Inc. grew its holdings in shares of Mesoblast Limited (NASDAQ:MESO) by 9.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 94,034 shares of the company’s stock after purchasing an additional 8,000 shares during the period. Lazari Capital Management Inc. owned about 0.06% of Mesoblast worth $116,000 at the end of the most recent quarter. 1.43% of the stock is owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.